Modality
Peptide
MOA
CGRPant
Target
MALT1
Pathway
Lipid Met
Pompe
Development Pipeline
Preclinical
~Oct 2019
→ ~Jan 2021
Phase 1
Apr 2021
→ Sep 2030
Phase 1Current
NCT05402109
901 pts·Pompe
2021-04→2030-03·Active
NCT04161532
1,853 pts·Pompe
2024-07→2030-09·Terminated
2,754 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-03-264.0y awayInterim· Pompe
2030-09-074.4y awayInterim· Pompe
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Active
P1
Termina…
Catalysts
Interim
2030-03-26 · 4.0y away
Pompe
Interim
2030-09-07 · 4.4y away
Pompe
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05402109 | Phase 1 | Pompe | Active | 901 | PASI75 |
| NCT04161532 | Phase 1 | Pompe | Terminated | 1853 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 |